PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Dilsher S. Dhoot, MD, discusses the functional benefits of pegcetacoplan in patients with geographic atrophy.
“I was honored to present first-time data here demonstrating that pegcetacoplan met, for the first time of any GA drug, a prespecified visual functional endpoint,” he said. “That endpoint is the number of scotomatous points at month 36, and we saw a reduction that was statistically significant in the number of scotomatous points in patients treated with pegcetacoplan.”